Research programme: stem cell therapeutics - Cornell University/Novo Nordisk
Latest Information Update: 28 Jun 2022
At a glance
- Originator Novo Nordisk
- Developer Cornell University; Novo Nordisk
- Class Antihyperglycaemics; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for research development in Diabetes-mellitus in Denmark (Parenteral)
- 28 Jun 2022 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)
- 23 May 2018 New profile created from MR 9241000